Domestic Programs
The CFAR Programs are organized by the diverse
expertise and experience of our faculty;
many of whose investigations span across
several Programs. The research evolves as
new ideas, talent and discoveries emerge.
| Research Program |
Description |
Program Director |
| Developmental Therapeutics |
This Program is focused on the development and evaluation of new drugs and treatment strategies to
combat HIV disease, and finding simpler regimens with less complications for those with HIV. Investigators
also study the pathogenesis of HIV disease in vivo by using therapeutic interventions that suppress HIV
replication or initiate anti-HIV immune responses. The Program includes studies supported by the Adult and
Pediatric AIDS CLinical Trials Units, the AIDS Malignancy Consortium (AMC), Studies of OCular Complications
with AIDS (SOCA) and the NIDA-funded Clinical Trials Node. |
Fred Valentine, M.D. |
| Viral Pathogenesis |
This Program aims to conduct studies to determine the cellular pathways of HIV entry and replication,
both in vitro and in vivo, and to detemrine the effects of this replication on the immune system |
DanLittman, M.D., Ph.D. |
| HIV-Associated Diseases |
This Program investigates the basic and clinical aspects of infections and complications of HIV disease
including: tuberculosis and pneumocystic carinii, ocular complications, such as CMV, and AIDS-related
malignancies. The Program focuses on the diagnosis and treatment of such complications, both locally and
abroad. |
William Rom, M.D., MPH |
| Pediatric HIV Disease |
This Program focuses on the transmission, pathogenesis, and treatment of HIV disease in children and
adolescents. It includes studies to prevent maternal-to-child transmission, both locally and abroad. |
William Borkowsky, M.D. |
| Epidemiology, Transmission and Prevention |
This Program aims to study the epidemiology and transmission of HIV and associated diseases, including hepatitis, syphillis, and tuberculosis, locally and abroad. These investigations help to develop intervention strategies for HIV prevention, including the feasibility of clinical trials of preventive vaccines. |
Michael Marmor, Ph.D. |